Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating sickle cell disease by targeting HbS polymerization.

William A Eaton1, H Franklin Bunn2

  • 1Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; and.

Blood
|April 8, 2017
PubMed
Summary

Sickle cell disease stems from hemoglobin S polymerization. This review explores five novel strategies to inhibit this process, offering new therapeutic avenues beyond current treatments targeting disease symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease.

Blood. Red cells & iron·2026
Same author

Pyruvate kinase deficiency modifies sickle hemoglobin carrier and sickle cell disease phenotypes in mice.

JCI insight·2026
Same author

Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.

Blood advances·2025
Same author

Therapeutic potential of the latest oxygen affinity-modifying agent, GBT021601, for treating sickle cell disease is questionable.

British journal of haematology·2024
Same author

Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease.

Haematologica·2024
Same author

In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation.

Blood advances·2024

Area of Science:

  • Hematology
  • Molecular Biology
  • Drug Discovery

Background:

  • Sickle cell disease (SCD) is caused by the polymerization of abnormal hemoglobin S (HbS).
  • This polymerization leads to red blood cell sickling, reduced flexibility, and vaso-occlusion.
  • Current treatments often address SCD complications rather than the root cause.

Purpose of the Study:

  • To explore molecular mechanisms for inhibiting HbS polymerization.
  • To present five distinct antipolymerization strategies.
  • To review the progress of antipolymerization drugs in clinical trials.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of distinct approaches to inhibit HbS polymerization.
  • Summary of current clinical trial data for antipolymerization agents.

Related Experiment Videos

Main Results:

  • Identified five distinct molecular strategies to inhibit HbS polymerization.
  • Highlighted the limited focus on antipolymerization therapies in drug development.
  • Provided an overview of the current landscape of antipolymerization drugs in clinical trials.

Conclusions:

  • Inhibiting HbS polymerization is a promising therapeutic strategy for SCD.
  • Further research and development of antipolymerization drugs are crucial.
  • Targeting the primary event of HbS polymerization offers a direct approach to SCD treatment.